75N95019D00012 - CRO SUPPORT FOR NCATS ANIMAL MODEL DEVELOPMENT AND...

This IDC contract for Pharmaceuticals > Research and Development was awarded in FY2019 on June 26, 2019 to Lovelace Biomedical Research Institute by National Center for Advancing Translational Sciences. There have been $18.2M in obligations to date with a ceiling value of $20M, showing a 91% burn rate so far on the contract. The contract was not competed under any preference program with 1 offer received. We expect a 5 year duration with ultimate completion date of June 29, 2024.

Lovelace Biomedical Research Institute is a contractor located in NM, doing primarily Pharmaceuticals > Research and Development work for Health and Human Services. The company receives $14.5M annually in federal awards (as of FY2020). Also, they have shown success winning IDC contracts concentrated mainly on a singular customer focused portfolio.

The Federal Government competes and awards an Indefinite Delivery Contract (IDC) to support requirements where the quantity and time of delivery are unknown. Typically referred to as Indefinite Delivery-Indefinite Quantity (IDIQ) contracts, the Government has the option of awarding a single or multiple award IDIQ. Once awarded, an IDIQ acts as a master agreement between the Federal Government and one or more contractors. On an as-needed basis, Federal buying organizations place orders, commonly referred to as Task Orders against an IDIQ, to purchase goods or services available through the IDIQ.

Read the full report

Buying Agency/Office

Health and Human Services » National Institutes of Health » National Center for Advancing Translational Sciences

Read the full report